Entactogen, first synthesized 1912; long history in medicine and policy
Amy Griffin has filed a federal defamation suit in Nevada accusing a former classmate of fabricating her abuse story and alleging that The New York Times published or amplified false claims. The case centers on allegations that Griffin stole another survivor’s story to fuel her bestselling memoir, The Tell, which remains under scrutiny in ongoing litigation and press inquiries.
A cross-border crackdown on county lines has led to multiple seizures, arrests and safeguarding actions as authorities target recruitment of vulnerable youths and drug distribution networks in Merseyside and across the UK.
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, with potential milestone payments. AtaiBeckley’s lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3, with initial results expected in 2029. The deal signals growing pharma interest in psychedelic therapies amid regulatory momentum.